硫氧还蛋白还原酶2在恶性肿瘤中的研究进展

doi:10.11904/j.issn.1002-3070.2018.02.017

Abstract

Abstract: Thioredoxin reductase (TrxR),a family of antioxidant family member, is widely distributed in the body.Its main function is to regulate the redox status of enzymes and transcription factors at the cellular level, and to participate in cell growth, proliferation and apoptosis.Meanwhile,it also provides favorable conditions for the occurrence and deterioration of malignant tumors.TrxR has three kinds of isoenzymes.TrxR2 distributed in mitochondria is also up-regulated in most malignant tumors and its expression is much higher than that in paracancerous tissues and normal tissues in recent studies.In addition, there is a lot of correlation between the up-regulated expression of TrxR2 and clinicopathological features as well as prognosis of many malignant tumors.It is speculated that TrxR2 may be involved in the occurrence, deterioration and metastasis in malignant tumors.This article reviews the progress of TrxR2 in several malignancies to explore whether or not TrxR2 can be a biomarker of malignancy and serve as a novel target for oncology treatment.

Key words: Thioredoxin(Trx), Thioredoxin reductase-2(TrxR2), Malignant tumor

CLC Number:

WU Yifei, LIU Baogang. Research progress of thioredoxin reductase 2 in malignant tumor[J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 174-178.

References

1 Dagnell M,Pace PE,Cheng Q,et al.Thioredoxin reductase 1 and NADPH directly protect protein tyrosine phosphatase 1B from inactivation during H₂O₂ exposure[J].J Biol Chem,2017,292(35):14371-14380.
2 Da Q,Wang P,Wang M,et al.Thioredoxin and NADPH-dependent thioredoxin reductase C regulation of Tetrapyrrole Biosynthesis[J].Plant Physiol,2017,175(2):652-666.
3 Radenkovic F,Holland O,Vanderlelie JJ,et al.Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation[J].Biochem Pharmacol,2017,146(2):42-52.
4 Yan J,Xu J,Fei Y,et al.TrxR2 deficiencies promote chondrogenic differentiation and induce apoptosis of chondrocytes through mitochondrial reactive oxygen species[J].Exp Cell Res,2016,344(1):67-75.
5 Li H,Xu C,Li Q,et al.Thioredoxin 2 offers protection against mitochondrial oxidative stress in H9c2 cells and against myocardial hypertrophy induced by hyperglycemia[J].Int J Mol Sci,2017,18(9):1-10.
6 Forred BJ,Daugaard DR,Titus BK,et al.Detoxification of mitochondrial oxidants and apoptotic signaling are facilitated by thioredoxin-2 and peroxiredoxin-3 during hyperoxic injury[J].PLoS One,2017,12(1):e0168777.
7 Fisher-Wellman KH,Mattox TA,Thayne K,et al.Novel role for thioredoxin reductase-2 in mitochondrial redox adaptations to obesogenic diet and exercise in heart and skeletal muscle[J].J Physiol,2013,591(14):3471-3486.
8 Prasad R,Chan LF,Hughes CR,et al.Thioredoxin reductase 2(TXNRD2)mutation associated with Familial Glucocorticoid Deficiency(FGD)[J].J Clin Endocrinol Metab,2014,99(8):1556-1563.
9 Hellfritsch J,Kirsch J,Schneider M,et al.Knockout of mitochondrial thioredoxin reductase stabilizes prolyl hydroxylase 2 and inhibits tumor growth and tumor-derived angiogenesis[J].Antioxid Redox Signal,2015,22(11):938-950.
10 Bu L,Li W,Ming Z,et al.Inhibition of TrxR2 suppressed NSCLC cell proliferation,metabolism and induced cell apoptosis through decreasing antioxidant activity[J].Life Sci,2017,178(1):35-41.
11 Chen W,Zou P,Zhao Z,et al.Selective killing of gastric cancer cells by a small molecule via targeting TrxR1 and ROS-mediated ER stress activation[J].Oncotarget,2016,7(13):16593-16609.
12 Fan C,Zheng W,Fu X,et al.Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine,a natural inhibitor of TrxR1 in vitro and in vivo[J].Cell Death Dis,2014,5(4):1-11.
13 Choi JH,Kim TN,Kim S,et al.Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas[J].Anticancer Res,2002,22(6):3331-3336.
14 Kitanovic I,Can S,Alborzinia H,et al.A deadly organometallic luminescent probe:anticancer activity of a Rel bisquinoline complex[J].Chemistry,2014,20(9):2496-2507.
15 Chen X,Zhou HJ,Huang Q,et al.Novel action and mechanism of auranofin in inhibition of vascular endothelial growth factor receptor-3-dependent lymph angiogenesis[J].Anticancer Agents Med Chem,2014,14(7):946-954.
16 Ng HL,Xiang M,Chew EH,et al.Design,synthesis,and biological evaluation of coupled bioactive scaffolds as potential anticancer agents for dual targeting of Dihydrofolate Reductase and Thioredoxin Reductase[J].J Med Chem,2017,60(5):1734-1745.
17 Garcia A,Machado RC,Grazul RM,et al.Novel antitumor adamantane-azole gold(I)complexes as potential inhibitors of thioredoxin reductase[J].J Biol Inorg Chem,2016,21(2):1-18.
18 Jayakumar S,Patwardhan RS,Pal D,et al.Mitochondrial targeted curcumin exhibits anticancer effects through disruption of mitochondrial redox and modulation of TrxR2 activity[J].Free Radic Biol Med,2017,113(2):530-538.
19 Zhang B,Zhang J,Peng S,et al.Thioredoxin reductase inhibitors:a patent review[J].Expert Opin Ther Pat,2017,27(5):547-556.
20 Cui T,Srivastava AK,Han C,et al.XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression[J].Oncotarget,2015,6(12):10060-10072.
21 Zheng X,Xu W,Sun R,et al.Synergism between thioredoxin reductase inhibitor ethaselen and sodium selenite in inhibiting proliferation and inducing death of human non-small cell lung cancer cells[J].Chem Biol Interact,2017,275(2):74-85.
22 Radenkovic F,Holland O,Vanderlelie JJ,et al.Selective inhibition of endogenous antioxidants with Auranofin causes mitochondrial oxidative stress which can be countered by selenium supplementation[J].Biochem Pharmacol,2017,146(2):42-52.
23 Yan J,Xu J,Fei Y,et al.TrxR2 deficiencies promote chondrogenic differentiation and induce apoptosis of chondrocytes through mitochondrial reactive oxygen species[J].Exp Cell Res,2016,344(1):67-75.
24 Powis G,Kirkpatrick DL.Thioredoxin signaling as a target for cancer therapy[J].Curr Opin Pharmacol,2007,7(4):392-397.
25 Fink EE,Mannava S,Bagati A,et al.Mitochondrial thioredoxin reductase regulates major cytotoxicity pathways of proteasome inhibitors in multiple myeloma cells[J].Leukemia,2016,30(1):104-111.
26 Jan YH,Heck DE,Dragomir AC,et al.Acetaminophen reactive intermediates target hepatic thioredoxin reductase[J].Chem Res Toxicol,2014,27(5):882-894.
27 Duan D,Zhang B,Yao J,et al.Gambogic acid induces apoptosis in hepatocellular carcinoma SMMC-7721 cells by targeting cytosolic thioredoxin reductase[J].Free Radic Biol Med,2014,69(4):15-25.
28 Zhou P,Ma L,Zhou J,et al.Effects of overexpression of miR-17-92 gene cluster on the biological characteristics of prostate cancer cells and its mechanism[J].Zhonghua Zhong Liu Za Zhi,2017,39(5):325-331.
29 Diebold L,Chandel NS.Mitochondrial ROS regulation of proliferating cells[J].Free Radic Biol Med,2016,100(2):86-93.
30 Mdps I,Begley U,Begley TJ,et al.Mitochondrial ROS control of cancer[J].Semin Cancer Biol,2017,47(2):57-66.
31 Zhang J,Li X,Han X,et al.Targeting the thioredoxin system for cancer therapy[J].Trends Pharmacol Sci,2017,38(9):794-808.
32 De Marco F,Bucaj E,Foppoli C,et al.Oxidative stress in HPV-driven viral carcinogenesis:redox proteomics analysis of HPV-16 dysplastic and neoplastic tissues[J].PLoS One,2012,7(3):e34366.
33 De MF.Oxidative stress and HPV carcinogenesis[J].Viruses,2013,5(2):708-731.
34 Bi W,Wang Y,Sun G,et al.Paclitaxel-resistant HeLa cells have up-regulated levels of reactive oxygen species and increased expression of taxol resistance gene 1[J].Pak J Pharm Sci,2014,27(4):871-878.
35 Park SJ,Kim HB,Piao C,et al.p53R2 regulates thioredoxinreductase activity through interaction with TrxR2[J].Biochem Biophys Res Commun,2017,482(4):706-712.
36 Patwardhan RS,Pal D,Checker R,et al.Baicalein induces cell death in murine T cell lymphoma via inhibition of thioredoxin system[J].Int J Biochem Cell Biol,2017,91(1):45-52.

[1]	ZHANG Maoxiang,SUN Huixin,SONG Bingbing. Analysis of the incidence and mortality of malignant tumors in Daoli District,Harbin,2008—2012 [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 261-265.
[2]	HAN Bangling,WANG Yimin,XUE Yingwei. Research progress in the relationship between neutrophils and malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 349-352.
[3]	ZHOU Jie, CHEN Yu, CHEN Daozhen. Application of nanoparticles in photodynamic therapy of tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 245-249.
[4]	HOU Siyu, CHEN Xiuwei. The structure and function of JMJD2B protein and its progress in the development of malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 250-253.
[5]	ZHANG Ting, HOU Guangying, WANG Xin, HE Yan. Research progress and clinical significance of QKI protein in malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 263-266.
[6]	JI Qiao, CHEN Li, HE Yuanqiao. Application of drug sensitivity from three-dimensional tissue in individualized precision medical treatment for tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 280-284.
[7]	LI Jing, ZHANG Yunyan. Research progress of miR-331-3p in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 125-129.
[8]	ZHANG Yongxin, HUANG He. Research progress and mechanism of Galectin-9 and various malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(2): 159-163.
[9]	HAN Xuejiao, LI Yanchun, SUN lichun, LU Hailing. Research progress of the relationship between 14-3-3ζ and malignant tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 543-547.
[10]	HUO Mingjuan,MENG Xiangcheng,SUN Ying,CHENG Li. Research progress of ALCAM in gynecological malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(4): 381-384.
[11]	HAO Lixiao,ZHANG Yunyan. Research progress of AIM2 in tumor [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(2): 175-178.
[12]	FAN Mingxv, ZHAO Yanbin, LI Boyang, WANG Yan. Research progress in the Notch pathway in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(1): 57-60.
[13]	WANG Jijun,HE Yan. The research progresses in USP22 in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(6): 551-554.
[14]	WANG Peng, WANG Zheng, ZHOU Zhixiang. Roles of p53 in the interaction with digestive malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 468-472.
[15]	SUN Zhi, CHEN Gongyan. The research progresses on RB1 in malignant tumors [J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(1): 80-83.

Research progress of thioredoxin reductase 2 in malignant tumor

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments